Becton, Dickinson and Company, commonly known as BD, is a global leader in the medical technology industry, headquartered in the United States. Founded in 1897, BD has established a strong presence in major operational regions, including North America, Europe, and Asia-Pacific. The company focuses on three primary business areas: BD Medical, BD Life Sciences, and BD Biosciences, offering innovative products and solutions that enhance patient care and improve healthcare outcomes. BD is renowned for its advanced medical devices, laboratory instruments, and diagnostic systems, which are distinguished by their commitment to quality and safety. With a rich history of innovation, BD has achieved significant milestones, including the development of the first safety-engineered needle. As a trusted partner in healthcare, BD continues to maintain a strong market position, recognised for its contributions to improving global health standards.
How does Bd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bd's score of 55 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Becton, Dickinson & Company (BD) reported total greenhouse gas emissions of approximately 6,633,180,000 kg CO2e. This figure includes emissions from all three scopes: Scope 1 emissions were about 162,475,000 kg CO2e, Scope 2 emissions totalled approximately 253,898,000 kg CO2e, and Scope 3 emissions accounted for around 6,633,180,000 kg CO2e. BD has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 50% by 2030 from a 2019 baseline. Additionally, the company is committed to achieving net-zero greenhouse gas emissions across its value chain by FY2050. Long-term targets include a 90% reduction in absolute Scope 1 and 2 emissions by 2050 and a 97% reduction in Scope 3 emissions per unit of sold product by 2050. These targets align with the science-based targets initiative (SBTi) and are designed to support the global goal of limiting temperature rise to 1.5°C. BD's commitment to sustainability reflects its proactive approach to addressing climate change and reducing its carbon footprint in the healthcare sector.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 96,333,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 514,801,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 158,622,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bd is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.